Life after DIAS II

International Journal of Stroke

Volumn 2, Issue 4, 2007, Pages 236-237

  Donnan, Geoffrey A ^a   Davis, Stephen M ^a  

^a HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOTEPLASE; PLACEBO; PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG DOSE ESCALATION; DRUG RESPONSE; FIBRINOLYTIC THERAPY; HUMAN; MORTALITY; NEUROIMAGING; NEUROLOGICAL COMPLICATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; STROKE;

ACUTE DISEASE; CLINICAL TRIALS, PHASE II AS TOPIC; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPERFUSION; SAMPLE SIZE; SELECTION BIAS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT FAILURE;

EID: 36249014323     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2007.00158.x     Document Type: Article

References (9)

1. The Internet Stroke Centre. DIAS-2 desmoteplase in acute ischemic stroke. http://www.Strokecenter.Org/trials/trialdetail.Aspx?Tid=515, 2007.
2. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
3. The Internet Stroke Centre. The International Stroke Trial (IST 3). http://www.Dcn.Ed.Ac.Uk/ist3/, 2007.
4. The Internet Stroke Centre. Epithet: Echoplanar imaging thrombolysis evaluation trial: http://www.Strokecenter.Org/trials/ trialdetail.Aspx?Tid=420, 2007.
5. Hacke W, Albers G, Al-Rawi Y et al. The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
6. Albers GW, Thijs VN, Wechsler L et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (defuse) study. Ann Neurol 2006; 60: 508-17.
7. Barber PA, Davis SM, Darby DG et al. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra. Neurology 1999; 52: 1125-32.
8. Parsons MW, Barber PA, Chalk J et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002; 51: 28-37.
9. Furlan AJ, Eyding D, Albers GW et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227-31.